Print this page

Biodefense

Products

Vaccinia Immune Globulin Intravenous (Human)
Vaccinia Immune Globulin Intravenous (Human) ("VIG") is Cangene's first biodefense product to be licensed by the U.S. Food & Drug Administration (“FDA”) and Health Canada. VIG contains specific antibodies to the Vaccinia virus (the virus used to make smallpox vaccine). VIG may be included as a component of national biodefense programs.

Cangene developed this product under contract to the U.S. government and has supplied the product to the U.S. Strategic National Stockpile. Other governments have also purchased VIG from Cangene.

Botulism Antitoxin Heptavalent
Botulism Antitoxin Heptavalent (“BAT”) is an investigational product containing antibodies specific for the seven botulinum toxin types: A, B, C, D, E, F, and G. Botulinum toxins are the bacterial toxins that cause botulism; these can occur naturally in improperly processed foods and have also been identified as a Category A bioterrorism threat.

Cangene developed this product under contract to the U.S. government and has supplied the product to the U.S. Strategic National Stockpile.

Anthrax Immune Globulin
Anthrax Immune Globulin (“AIG”) is an investigational product derived from plasma obtained from donors immunized with the Anthrax vaccine. AIG contains antibodies specific for Bacillus anthracis, the bacteria that cause anthrax. Anthrax is a naturally occurring bacterial infection in certain animal populations and can infect humans exposed to them. It has also been identified as a Category A bioterrorism threat.

Cangene developed this product under contract to the U.S. government and has supplied the product to the U.S. Strategic National Stockpile.

Ebola/Marburg antibodies
Cangene is developing Ebola/Marburg monoclonal and polyclonal antibodies as therapeutic products and they are currently in early-stage development. Ebola and Marburg viruses cause hemorrhagic fever.

Cangene has received funding for this project from the Canadian government's Chemical, Biological, Radiological and Nuclear incident, Research & Technology initiative (“CRTI”).